<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978740</url>
  </required_header>
  <id_info>
    <org_study_id>MOOMA</org_study_id>
    <nct_id>NCT04978740</nct_id>
  </id_info>
  <brief_title>Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)</brief_title>
  <official_title>Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one&#xD;
      or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the&#xD;
      general population is 1 in 10,000.&#xD;
&#xD;
      This pathology is due to the proliferation of a mast cell clone and the excessive release of&#xD;
      inflammatory mediators which lead to abnormal tissue infiltration.&#xD;
&#xD;
      To date, there are only a few cases reporting ocular and orbital manifestations of&#xD;
      mastocytosis.&#xD;
&#xD;
      Our prospective, interventional and single-center study consist in describing the ocular&#xD;
      functional manifestations and ocular surface abnormalities of patients with systemic and&#xD;
      cutaneous mastocytosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient with systemic or cutaneous mastocytosis will be included in the study. Data about&#xD;
      organ involvement of mastocytosis will be collected. Participants will be screened with a&#xD;
      medical and eye disease history. They will also have an eye exam.&#xD;
&#xD;
      Participants will provide a tears sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects with mastocytosis presenting eye abnormalities</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Number of patients with functional complaints or abnormalities of the surface, orbit, anterior and posterior segment of the eyeball.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nature and Frequency of eye abnormalities</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Details of functional complaints, abnormalities of various specialized examinations such as ocular tonometry to determine intraocular pressure, Refraction assessment, Retina examination, Slit lamp examination, Visual acuity, Schirmer's test, Corneal topography, Funduscopic examination, Optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factor of eye abnormalities</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Significative association with a mastocytosis subtype or certain organ involvements or biological abnormalities</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mast Cell Activation Disease</condition>
  <condition>Mast Cell Activation Syndrome</condition>
  <condition>Mast Cell Disease</condition>
  <condition>Urticaria Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Participants affected by cutaneous and systemic mastocytosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants affected by cutaneous and systemic mastocytosis with or without eye disabilities</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ophthalmological examination</intervention_name>
    <description>Eye examination :&#xD;
Ocular tonometry to determine intraocular pressure Refraction assessment Retina examination Slit lamp examination Visual acuity Schirmer's test Corneal topography Funduscopic examination Optical coherence tomography</description>
    <arm_group_label>Participants affected by cutaneous and systemic mastocytosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of mastocytosis&#xD;
&#xD;
          -  Male or female, 18 years of age and over&#xD;
&#xD;
          -  Ability to understand and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disorders that do not allow good visualization of the posterior pole (cataract,&#xD;
             intravitreal hemorrhage)&#xD;
&#xD;
          -  Patients with another ocular pathology that may bias the results (corneal dystrophy,&#xD;
             dysthyroid orbitopathy, retinal pathologies)&#xD;
&#xD;
          -  History of refractive surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie MASSON REGNAULT, Doctor</last_name>
    <phone>0666798314</phone>
    <email>marie_masson_regnault@hotmail.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masson Regnault</name>
      <address>
        <city>Poitiers</city>
        <state>Nouvelle Aquitaine</state>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie MASSON REGNAULT, Doctor</last_name>
      <phone>0666798314</phone>
      <email>marie_masson_regnault@hotmail.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Urticaria Pigmentosa</mesh_term>
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

